

09-06-02

#44264
9-12-02

EXPRESS MAIL CERTIFICATE

TECH CENTER 1600/2900

SEP 09 2002

RECEIVED

"Express Mail" Label No. : EV 032 108 785 US
Serial No. : 10/091,609
Applicant(s) : Adnan M. M. Mjalli et al.
Filing Date : March 5, 2002
Title: : BENZIMIDAZOLE DERIVATIVES AS
THERAPEUTIC AGENTS
Examiner : Unassigned
Group Art Unit : 1626
Type of Document(s) : Transmittal Form
Supplemental Information Disclosure Statement
(in duplicate)
PTO/SB/08A (1 page)
References: 4
Return Postcard

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

 (signature)
Madge Leonard

Date of Deposit: 9-5-02



Please type a plus sign (+) inside this box →


+

EV 032 108 785 US PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/091,609
		Filing Date	March 5, 2002
		First Named Inventor	Adnan M. M. Mjalli
		Group Art Unit	1626
		Examiner Name	Unassigned
Total Number of Items in This Submission (including Transmittal Form)	9	Attorney Docket Number	41305-271622 (2001-07)
ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (in duplicate) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Express Mail Certificate – EV 032 108 785 US PTO/SB/08A (1 page) References: 4 Return Postcard	RECEIVED SEP 09 2002 TECH CENTER 1600/2900
Remarks			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm or Individual name	Cynthia B. Rothschild, Esq. Reg. No. 47,040		
Signature			
Date	9/5/02		
CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service's first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: _____			
Typed or printed name	SENT VIA EXPRESS MAIL		
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

41305-271622
WINLIB01:966516.1



RECEIVED

SEP 09 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Adnan M. M. Mjalli et al.
U.S. Serial No. : 10/091,609
U.S. Filing Date : March 5, 2002
For : BENZIMIDAZOLE DERIVATIVES AS
THERAPEUTIC AGENTS
Art Unit : 1626
Examiner : Unassigned

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants submit herewith on Form PTO/SB/08A a listing of documents known to the Applicants and/or their attorneys. Applicants respectfully request consideration of the cited documents and making the same of record in the prosecution of the above-identified application. In so doing, Applicants do not waive any rights to appropriate action to establish patentability over the listed documents should they be applied as references against the claims of the present application. Copies of four (4) documents are enclosed.

One of the references is a French language patent 2160719 to Fauran et al., for which no translation is readily available. In part, FR 2160719 appears to disclose derivatives of 1-(2'-benzimidazolyl)-1-propanol, their method of preparation, and therapeutic applications. Patent FR2160709 was cited in the International Search Report for the PCT application, PCT/US02/06706, corresponding to the above-cited application. An English language version the search report, indicating the degree of relevance and the portions of FR2160709 relevant to the PCT application is submitted herewith.

For the document listed in "Other Documents," Applicants have listed the mailing date shown on the document. Applicants make no representation as to the publication or mailing date, if any, of the documents.

This Supplemental Information Disclosure Statement should not be construed as a representation that more material information does not exist or that a search of the relevant art has been made.

This Supplemental Information Disclosure Statement is being submitted prior to the mailing of a first Office Action in this application, and, therefore, no certification or fee is required (37 C.F.R. § 1.97b(3)). However, should any fees be due, the Commissioner is authorized to charge such fees to Deposit Account No. 16-1435. A duplicate of this sheet is attached for that purpose.


Date: 9/5/02


KILPATRICK STOCKTON LLP
1001 West Fourth Street
Winston-Salem, North Carolina 27101-2400
(336) 747-7541 Phone
(336) 607-7500 Facsimile

Attorney Docket No: 41305-271622

41305-271622
WINLIB01:966495.1

Respectfully submitted,


Cynthia B. Rothschild
Reg. No. 47,040



Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449 APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/091,609
Filing Date	March 5, 2002
First Named Inventor	Adnan M. M. Mjalli
Group Art Unit	1626
Examiner Name	Unassigned
Attorney Docket Number	41305-271622 (2001-07)
Express Mail Certificate	EV 032 108 785 US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1	3,951,968		Claude P. Fauran et al.	04-20-76	
	2	6,316,474		John A. McCauley et al.	11-13-01	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ³	Number ⁴	Kind Code ² (if known)				
	3	FR	2160719		Fauran	07-06-73		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4	PCT Notification of Transmittal of the International Search Report corresponding to PCT application from PCT/US02/06706 ("Benzimidazole Derivatives as Therapeutic Agents")	✓

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

41305-271622
WINLIB01:966492.1

RECEIVED
SEP 09 2002
TECH CENTER 1600/2900